KITE

AFTER DOUBLING MONEY IN THIS FAMOUS BIOTECH RELATED TO APPLE, WHAT IS NEXT? $AAAP $AAPL $NEOS $NVS $PDLI $GILD $JUNO $ZIOP $BLCM $BLUE

Not long ago, French pharmaceutical company Advanced Accelerator Applications got a lot of publicity. Now it’s getting bought out. The late Apple AAPL, co-founder Steve Jobs died from pancreatic cancer, specifically from a neuroendocrine tumor, or islet cell carcinoma. Advanced Accelerator Applications AAAP,  became famous because of its work on

Read More

INTELLIGENCE: CONGRATULATIONS TO THOSE WHO BOUGHT BIOTECH FIRM KITE PHARMA, $180 BUYOUT OFFER $KITE $GILD

This post was just published on ZYX Buy Change Alert.   KITE is a biotech firm focused on cancer using engineered T-cell therapy.  When The Arora Report had provided intelligence on KITE it was trading around $54.27.  Now GILD is buying it at $180.  If holding, consider taking profits and exiting the

Read More

TRUMP’S ‘OBAMACARE LITE’ PRESENTS OPPORTUNITIES AND PERILS FOR INVESTORS $XBI $MDT $BSX $EW $CYH $THC $PFE $JNJ $MRK $BMY $TEVA $MYL

Republicans have finally produced a detailed plan to repeal and replace the Affordable Care Act, also known as Obamacare. Setting aside politics and viewing the plan neutrally, two things jump out. First, the House Republicans’ plan keeps the basic framework of Obamacare. No wonder some are calling it “Obamacare Lite.”

Read More

OBAMACARE IS DEAD, WELCOME TRUMPCARE OPPORTUNITIES! $SPY $XLV $XHS $PJP $XBI $IHI $BMY $JNJ $PFE $MRK $ABT $ABBV $LLY $HUM $UNH $AET $ANTH $CI $HCE $CVH $THC $CNC $MOH

Democrats will fight tooth and nail to save Obamacare, but given the flaws in the plan, they are not likely to succeed. Obamacare in its current form is the walking dead. Trump has said that he will replace Obamacare with something better. In his speeches, Trump outlined certain key points

Read More

INTELLIGENCE: CAR-T CANCER IMMUNOTHERAPY PROMISING BUYOUT TARGETS AFTER ASTRAZENECA $AZN $CLLS $JUNO $BLCM $XON $ZIOP $KITE $BLUE $ADXS $LBIO

This post was just published on ZYX Buy Change Alert. For us to recommend, a stock must pass at least four of the six screens. We prefer a stock to meet all six screens. Our rigorous criteria has led to enviable performance over a long period of time. We periodically provide

Read More

Do you want to gain an edge in the markets? Join thousands of your fellow investors and money managers to subscribe to Generate Wealth newsletter.

 

FREE FOREVER

Follow The Most Accurate Stock Market Analysis

Unrivaled Insights
In Bull and Bear Markets

Generate Wealth Newsletter
Free Forever

Generate Wealth Newsletter
Free Forever